S Novello

Summary

Affiliation: University of Turin
Country: Italy

Publications

  1. ncbi Lung cancer and women
    Silvia Novello
    Department of Clinical and Biological Sciences, S Luigi Hospital, University of Torino, Orbassano, Torino, Italy
    Future Oncol 4:705-16. 2008
  2. ncbi Gemcitabine (Gemzar)-based induction chemotherapy in non-small-cell lung cancer
    Giorgio Vittorio Scagliotti
    Thoracic Oncology Unit, Department of Clinical and Biological Sciences, S Luigi Hospital, University of Torino, Orbassano, Turin, Italy
    Lung Cancer 38:S13-9. 2002
  3. ncbi Selection of suitable reference genes for accurate normalization of gene expression profile studies in non-small cell lung cancer
    Silvia Saviozzi
    Department of Clinical and Biological Sciences, University of Torino, Regione Gonzole 10, 10043 Orbassano, Torino, Italy
    BMC Cancer 6:200. 2006
  4. ncbi Phase III study in stage IV non-small-cell lung cancer patients treated with two courses of cisplatin/gemcitabine followed by a randomization to three additional courses of the same combination or gemcitabine alone
    S Novello
    Department of Clinical and Biological Sciences, Thoracic Oncology Unit, San Luigi Hospital, University of Turin, Orbassano, Turin, Italy
    Ann Oncol 18:903-8. 2007
  5. ncbi Toward therapies tailored to patient characteristics
    Silvia Novello
    University of Turin, Turin, Italy
    J Thorac Oncol 2:S38-41. 2007
  6. ncbi Maintenance therapy in NSCLC: why? To whom? Which agent?
    Silvia Novello
    Thoracic Oncology Unit, University of Turin, AOU, San Luigi Orbassano, Italy
    J Exp Clin Cancer Res 30:50. 2011
  7. ncbi Phase II study of sunitinib in patients with non-small cell lung cancer and irradiated brain metastases
    Silvia Novello
    University of Turin, Orbassano, Turin, Italy
    J Thorac Oncol 6:1260-6. 2011
  8. ncbi Phase II study of continuous daily sunitinib dosing in patients with previously treated advanced non-small cell lung cancer
    S Novello
    Department of Clinical and Biological Sciences, Thoracic Oncology Unit, University of Turin, Orbassano, Turin, Italy
    Br J Cancer 101:1543-8. 2009
  9. ncbi Safety and resource utilization by non-small cell lung cancer histology: results from the randomized phase III study of pemetrexed plus cisplatin versus gemcitabine plus cisplatin in chemonaïve patients with advanced non-small cell lung cancer
    Silvia Novello
    Thoracic Oncology Unit, University of Torino, San Luigi Hospital, Torino, Italy
    J Thorac Oncol 5:1602-8. 2010
  10. ncbi Randomised multicenter phase II study of two schedules of docetaxel and gemcitabine or cisplatin/gemcitabine followed by docetaxel as first line treatment for advanced non-small cell lung cancer
    Silvia Novello
    Department of Clinical and Biological Sciences, Thoracic Oncology Unit, University of Turin, Italy
    Lung Cancer 66:327-32. 2009

Detail Information

Publications64

  1. ncbi Lung cancer and women
    Silvia Novello
    Department of Clinical and Biological Sciences, S Luigi Hospital, University of Torino, Orbassano, Torino, Italy
    Future Oncol 4:705-16. 2008
    ....
  2. ncbi Gemcitabine (Gemzar)-based induction chemotherapy in non-small-cell lung cancer
    Giorgio Vittorio Scagliotti
    Thoracic Oncology Unit, Department of Clinical and Biological Sciences, S Luigi Hospital, University of Torino, Orbassano, Turin, Italy
    Lung Cancer 38:S13-9. 2002
    ....
  3. ncbi Selection of suitable reference genes for accurate normalization of gene expression profile studies in non-small cell lung cancer
    Silvia Saviozzi
    Department of Clinical and Biological Sciences, University of Torino, Regione Gonzole 10, 10043 Orbassano, Torino, Italy
    BMC Cancer 6:200. 2006
    ..Aim of this study was to identify and validate RGs for use in the differentiation of normal and tumor lung expression profiles...
  4. ncbi Phase III study in stage IV non-small-cell lung cancer patients treated with two courses of cisplatin/gemcitabine followed by a randomization to three additional courses of the same combination or gemcitabine alone
    S Novello
    Department of Clinical and Biological Sciences, Thoracic Oncology Unit, San Luigi Hospital, University of Turin, Orbassano, Turin, Italy
    Ann Oncol 18:903-8. 2007
    ....
  5. ncbi Toward therapies tailored to patient characteristics
    Silvia Novello
    University of Turin, Turin, Italy
    J Thorac Oncol 2:S38-41. 2007
  6. ncbi Maintenance therapy in NSCLC: why? To whom? Which agent?
    Silvia Novello
    Thoracic Oncology Unit, University of Turin, AOU, San Luigi Orbassano, Italy
    J Exp Clin Cancer Res 30:50. 2011
    ....
  7. ncbi Phase II study of sunitinib in patients with non-small cell lung cancer and irradiated brain metastases
    Silvia Novello
    University of Turin, Orbassano, Turin, Italy
    J Thorac Oncol 6:1260-6. 2011
    ..This phase II study evaluated the antitumor activity and safety of sunitinib in patients with pretreated NSCLC and irradiated brain metastases...
  8. ncbi Phase II study of continuous daily sunitinib dosing in patients with previously treated advanced non-small cell lung cancer
    S Novello
    Department of Clinical and Biological Sciences, Thoracic Oncology Unit, University of Turin, Orbassano, Turin, Italy
    Br J Cancer 101:1543-8. 2009
    ..Sunitinib malate (SUTENT) has promising single-agent activity given on Schedule 4/2 (4 weeks on treatment followed by 2 weeks off treatment) in advanced non-small cell lung cancer (NSCLC)...
  9. ncbi Safety and resource utilization by non-small cell lung cancer histology: results from the randomized phase III study of pemetrexed plus cisplatin versus gemcitabine plus cisplatin in chemonaïve patients with advanced non-small cell lung cancer
    Silvia Novello
    Thoracic Oncology Unit, University of Torino, San Luigi Hospital, Torino, Italy
    J Thorac Oncol 5:1602-8. 2010
    ..Selected grade 3/4 toxicities and resource utilization favored pemetrexed in the overall population, but detailed safety results by histology have not been reported...
  10. ncbi Randomised multicenter phase II study of two schedules of docetaxel and gemcitabine or cisplatin/gemcitabine followed by docetaxel as first line treatment for advanced non-small cell lung cancer
    Silvia Novello
    Department of Clinical and Biological Sciences, Thoracic Oncology Unit, University of Turin, Italy
    Lung Cancer 66:327-32. 2009
    ..In the attempt to optimize the efficacy of chemotherapy in advanced non-small cell lung cancer (NSCLC) several strategies need to be investigated including the use of non-platinum combinations and the sequential use of different agents...
  11. ncbi Phase I/II dose finding study of paclitaxel and carboplatin in advanced non-small cell lung cancer
    G V Scagliotti
    Department of Clinical and Biological Sciences, University of Torino, Azienda Ospedliera S Luigi, Orbassano, Italy
    Lung Cancer 25:39-46. 1999
    ....
  12. ncbi ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine
    P Ceppi
    Thoracic Oncology Unit, Orbassano, Torino, Italy
    Ann Oncol 17:1818-25. 2006
    ..Prospective pharmacogenomic studies represent a research priority in early and advanced NSCLC...
  13. ncbi Excision repair cross complementing-1 and topoisomerase IIalpha gene expression in small-cell lung cancer patients treated with platinum and etoposide: a retrospective study
    Paolo Ceppi
    Thoracic Oncology Unit, University of Torino, S Luigi Hospital, Orbassano Torino, Italy
    J Thorac Oncol 3:583-9. 2008
    ..Aim of the study was to quantify ERCC1, RRM1, and TopoIIalpha mRNA expression profile as predictive factors for response and survival in SCLC patients treated with platinum/etoposide...
  14. ncbi Phase II study of high-dose paclitaxel and carboplatin in previously untreated, unresectable non-small cell lung cancer
    S Novello
    Department of Clinical and Biological Sciences, University of Torino, Azienda Ospedaliera S. Luigi, Regione Gonzole 10, 10043 Orbassano, Turin, Italy
    Lung Cancer 34:261-9. 2001
    ..CONCLUSION: In advanced NSCLC, the combination carboplatin-paclitaxel at doses of AUC 6 mg/ml per minute and 225 mg/ml every 3 weeks, is both active and relatively well-tolerated...
  15. ncbi Cost-minimisation analysis comparing gemcitabine/cisplatin, paclitaxel/carboplatin and vinorelbine/cisplatin in the treatment of advanced non-small cell lung cancer in Italy
    S Novello
    Department of Clinical and Biological Sciences, University of Torino, Turin, Italy
    Lung Cancer 48:379-87. 2005
    ..Based on resource consumption in a clinical trial, Gem/Cis had the lowest overall mean costs of the three chemotherapy regimens. Gem/Cis therefore has the potential to save costs in the treatment of advanced NSCLC in Italy...
  16. ncbi Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer
    Giorgio Scagliotti
    Department of Clinical and Biological Sciences, University of Turin, San Luigi Hospital, Regione Gonzole 10, Orbassano, Torino, Italy 10043
    J Clin Oncol 28:1835-42. 2010
    ..4%), hand-foot skin reaction (7.8%), and diarrhea (3.5%). CONCLUSION No clinical benefit was observed from adding sorafenib to CP chemotherapy as first-line treatment for NSCLC...
  17. ncbi Prevalence of adrenal incidentaloma in a contemporary computerized tomography series
    S Bovio
    Internal Medicine I, Department of Biological and Clinical Sciences, ASO San Luigi, University of Turin, Italy
    J Endocrinol Invest 29:298-302. 2006
    ..Notwithstanding that our subjects were at increased risk of lung cancer, the rate of adrenal metastases was low. We think that the present results can be generalized even if we may disclose the lack of histological diagnosis...
  18. ncbi Pemetrexed and its emerging role in the treatment of thoracic malignancies
    Giorgio V Scagliotti
    University of Torino, Department of Clinical and Biological Sciences, S Luigi Hospital Thoracic Oncology Unit, Regione Gonzole 10 10043 Orbassano, Turin, Italy
    Expert Opin Investig Drugs 12:853-63. 2003
    ..Here, the current data for pemetrexed in treating thoracic malignancies are reviewed, with special focus on malignant pleural mesothelioma and non-small cell lung cancer...
  19. ncbi Efficacy of neoadjuvant strategies with gemcitabine and other chemotherapy in resectable non-small cell lung cancer: a combined modality approach
    Giorgio V Scagliotti
    Department of Clinical and Biological Sciences, Thoracic Oncology Unit, S. Luigi Hospital, University of Torino, Orbassano, Italy
    Semin Oncol 30:13-8. 2003
    ....
  20. ncbi Multidrug resistance in non-small-cell lung cancer
    G V Scagliotti
    University of Turin, Department of Clinical and Biological Sciences, Azienda Ospedaliera S Luigi Orbassano, Torino, Italy
    Ann Oncol 10:S83-6. 1999
    ..In lung cancer the role of the different forms of multidrug resistance is complex and only partially understood...
  21. ncbi Epidermal growth factor receptor overexpression correlates with a poor prognosis in completely resected non-small-cell lung cancer
    G Selvaggi
    Thoracic Oncology Unit, Department of Clinical and Biological Sciences, University of Torino, Torino, Italy
    Ann Oncol 15:28-32. 2004
    ..We designed a prospective study to test epidermal growth factor receptor (EGFR) expression by immunohistochemistry (IHC) in resected stage I-IIIA non-small-cell lung cancer (NSCLC) and to correlate overexpression with survival...
  22. ncbi Chemotherapy for non-small-cell lung cancer. Part 1: Early-stage disease
    Silvia Novello
    University of Turin, Department of Clinical and Biological Sciences, San Luigi Hospital, Turin, Italy
    Oncology (Williston Park) 17:357-64. 2003
    ..The first part of this article, which concludes next month, will address adjuvant and neoadjuvant chemotherapy in early-stage non-small-cell lung cancer...
  23. ncbi HER-2/neu overexpression in patients with radically resected nonsmall cell lung carcinoma. Impact on long-term survival
    Giovanni Selvaggi
    Department of Clinical and Biological Sciences, University of Torino, Azienda Ospedaliera S. Luigi, Regione Gonzole, 10, 10043 Orbassano, Torino, Italy
    Cancer 94:2669-74. 2002
    ..HER-2/neu overexpression may be a valuable prognostic factor as well as a potential target for biologic therapies...
  24. ncbi Pemetrexed combined with oxaliplatin or carboplatin as first-line treatment in advanced non-small cell lung cancer: a multicenter, randomized, phase II trial
    Giorgio V Scagliotti
    Department of Clinical and Biological Sciences, Thoracic Oncology Unit, S Luigi Gonzaga Hospital, University of Torino, Regione Gonzole 10 00043 Orbassano, Turin, Italy
    Clin Cancer Res 11:690-6. 2005
    ..To determine efficacy and toxicity of two pemetrexed-based regimens in chemonaive patients with locally advanced or metastatic non-small cell lung cancer...
  25. ncbi State of the art in mesothelioma
    G V Scagliotti
    University of Turin, Department of Clinical and Biological Sciences, S. Luigi Hospital, Orbassano (Torino, Italy
    Ann Oncol 16:ii240-5. 2005
  26. ncbi Three-year findings of an early lung cancer detection feasibility study with low-dose spiral computed tomography in heavy smokers
    S Novello
    University of Turin, Department of Clinical and Biological Sciences, Thoracic Oncology Unit, San Luigi Hospital, Orbassano Turin, Italy
    Ann Oncol 16:1662-6. 2005
    ....
  27. ncbi Current status of adjuvant chemotherapy in NSCLC
    G V Scagliotti
    Department of Clinical and Biological Sciences, S. Luigi Hospital, Thoracic Oncology Unit, University of Turin, Torino, Italy
    Ann Oncol 17:v62-3. 2006
  28. ncbi The pulmonary nodule: clinical and radiological characteristics affecting a diagnosis of malignancy
    L Cardinale
    S C D U Radiologia, Ospedale San Luigi Gonzaga, Regione Gonzole 10, Orbassano, Torino, Italy
    Radiol Med 114:871-89. 2009
    ..The aim of this paper is to summarise the approach to pulmonary nodules from the point of view of the radiologist, oncologist and thoracic surgeon...
  29. ncbi Melphalan monitoring during hyperthermic perfusion of isolated limb for melanoma: pharmacokinetic study and 99mTc-albumin microcolloid technique
    L Cattel
    Dipartimento di Scienza e Tecnologia del Farmaco, Universita degli Studi di Torino, Italy
    Anticancer Res 21:2243-8. 2001
    ..The kinetics of melphalan leakage from extracorporeal fluid to the peripheral blood was studied in ten patients undergoing hyperthermic isolation perfusion of the lower limbs as an adjuvant treatment in high-risk melanoma...
  30. ncbi Epidermal growth factor ligand/receptor loop and downstream signaling activation pattern in completely resected nonsmall cell lung cancer
    Marco Volante
    Department of Clinical and Biological Sciences, University of Turin, Turin, Italy
    Cancer 110:1321-8. 2007
    ....
  31. ncbi Pemetrexed in front-line chemotherapy for advanced non-small-cell lung cancer
    Giorgio V Scagliotti
    University of Torino, Department of Clinical and Biological Sciences, S Luigi Gonzaga Thoracic Oncology Unit, Orbassano Torino, Italy
    Oncology (Williston Park) 18:32-7. 2004
    ..This article briefly summarizes the current evidence that supports the role of pemetrexed-based combinations in clinical trials for chemonaive patients with advanced NSCLC...
  32. ncbi Polymerase eta mRNA expression predicts survival of non-small cell lung cancer patients treated with platinum-based chemotherapy
    Paolo Ceppi
    Thoracic Oncology Unit, Department of Clinical and Biological Sciences, University of Turin, San Luigi Hospital, Orbassano Torino, Italy
    Clin Cancer Res 15:1039-45. 2009
    ..The aim of the present study was to investigate the role of Pol eta mRNA expression levels in non-small cell lung cancer (NSCLC)...
  33. ncbi Non-small cell lung cancer exhibits transcript overexpression of genes associated with homologous recombination and DNA replication pathways
    Silvia Saviozzi
    Genomics and Informatics Unit, University of Torino, Turin, Italy
    Cancer Res 69:3390-6. 2009
    ..In conclusion, genes belonging to DNA repair/replication pathways are overexpressed in NSCLC and are associated with a more aggressive phenotype...
  34. ncbi Updated clinical information on multitargeted antifolates in lung cancer
    Giorgio V Scagliotti
    Department of Clinical and Biological Sciences, University of Torino, Torino, Italy
    Clin Lung Cancer 10:S35-40. 2009
    ..These hypothesis-generating findings are currently validated in prospective studies...
  35. ncbi Epidermal growth factor receptor gene in primary tumor and metastatic sites from non-small cell lung cancer
    Lorenzo Daniele
    Department of Biomedical Sciences and Human Oncology, University of Turin, Turin, Italy
    J Thorac Oncol 4:684-8. 2009
    ..Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors are capable of reducing brain and adrenal metastases. However, the EGFR status may be discordant between primary NSCLC and the corresponding metastases...
  36. ncbi Nonsmall cell lung cancer in never smokers
    Giorgio V Scagliotti
    Department of Clinical and Biological Sciences, University of Turin, S Luigi Hospital, Regione Gonzole, 10, Orbassano, Turin 10043, Italy
    Curr Opin Oncol 21:99-104. 2009
    ..To summarize the available knowledge about nonsmall cell lung cancer (NSCLC) in never smokers in terms of biological and clinical-pathological findings...
  37. ncbi Effects of Src kinase inhibition induced by dasatinib in non-small cell lung cancer cell lines treated with cisplatin
    Paolo Ceppi
    University of Turin, Department of Clinical and Biological Sciences, San Luigi Hospital, Regione Gonzole 10, Orbassano, Italy
    Mol Cancer Ther 8:3066-74. 2009
    ..The data of this study support further clinical studies aimed to evaluate the efficacy of Src-inhibiting agents in combination with cisplatin in the treatment of NSCLC...
  38. ncbi Bone sialoprotein is predictive of bone metastases in resectable non-small-cell lung cancer: a retrospective case-control study
    Mauro Papotti
    Department of Clinical and Biological Sciences, University of Turin, San Luigi Hospital, Orbassano, Turin, Italy
    J Clin Oncol 24:4818-24. 2006
    ..Currently, there are no predictive or diagnostic markers to identify high-risk patients for metastatic bone dissemination...
  39. ncbi Adjuvant therapy in completely resected non-small-cell lung cancer
    Giorgio V Scagliotti
    Department of Clinical and Biological Sciences, University of Turin, S Luigi Hospital, Thoracic Oncology Unit, Regione Gonzole, 10, 10043 Orbassano Torino, Italy
    Curr Oncol Rep 5:318-25. 2003
    ..It is hoped that a specific meta-analysis will be performed on the basis of these data...
  40. ncbi Squamous cell carcinoma of the lung compared with other histotypes shows higher messenger RNA and protein levels for thymidylate synthase
    Paolo Ceppi
    Thoracic Oncology Unit, Department of Clinical and Biological Sciences, University of Turin, San Luigi Hospital, Orbassano, Torino, Italy
    Cancer 107:1589-96. 2006
    ..This information may be useful in selecting which patients with NSCLC should receive treatment with TS-inhibiting agents...
  41. ncbi Current development of adjuvant treatment of non-small-cell lung cancer
    Giorgio V Scagliotti
    Department of Clinical and Biological Sciences, University of Turin, S Luigi Hospital, Thoracic Oncology Unit, Orbassano Torino, Italy
    Clin Lung Cancer 6:S63-70. 2004
    ..Genomic- and proteomic-driven chemotherapy as well as molecularly targeted therapies may represent additional areas of near-future clinical investigations...
  42. ncbi Caveolin-1 expression in lung carcinoma varies according to tumour histotype and is acquired de novo in brain metastases
    Paola Cassoni
    Department of Biomedical Sciences and Oncology, University of Turin, Turin, Italy
    Histopathology 55:20-7. 2009
    ..To study caveolin-1 (Cav-1) expression in metastatic lung carcinomas...
  43. ncbi The biology of epidermal growth factor receptor in lung cancer
    Giorgio V Scagliotti
    Department of Clinical and Biological Sciences, S Luigi Gonzaga, University of Torino, Thoracic Oncology Unit, Torino, Italy
    Clin Cancer Res 10:4227s-4232s. 2004
    ..New technologies such as nucleotide arrays and proteomics will help to elucidate the issue by providing information on how EGFR signaling may affect the expression of genes and proteins in cancer cells...
  44. ncbi Adjuvant chemotherapy after complete resection for early stage NSCLC
    Giorgio Scagliotti
    Department of Clinical and Biological Sciences, University of Torino, Azienda Ospedaliera S Luigi, Thoracic Oncology Unit, Orbassano, Torino, Italy
    Lung Cancer 42:S47-51. 2003
    ..Data regarding large-scale adjuvant chemotherapy trials, closed for the accrual almost four to five years ago, will be fully available soon and, hopefully, a specific meta-analysis will be performed...
  45. ncbi Accuracy of CT-guided transthoracic needle biopsy of lung lesions: factors affecting diagnostic yield
    A M Priola
    Radiologia Diagnostica, Universita degli Studi di Torino, A S O San Luigi Gonzaga, Regione Gonzole 10, Orbassano, Turin, Italy
    Radiol Med 112:1142-59. 2007
    ..This study was performed to analyse the variables affecting the diagnostic accuracy of computed tomography (CT)-guided transthoracic needle biopsy of pulmonary lesions...
  46. ncbi Chemotherapy for non-small-cell lung cancer. Part 2: Advanced disease
    Silvia Novello
    Thoracic Oncology Unit, Department of Clinical and Biological Sciences, San Luigi Hospital, Regione Gonzole 10, 10043 Orbassano, Torino, Italy
    Oncology (Williston Park) 17:457-64, 469-71; discussion 471, 478-80, 483-4. 2003
    ..Part 2 of this two-part article addresses the role of chemotherapy in locally advanced and advanced NSCLC, including the use of novel agents, considerations in elderly patients, and studies of second-line treatment...
  47. ncbi Role of erythropoietin in the treatment of lung cancer associated anaemia
    G V Scagliotti
    Department of Clinical and Biological Sciences, University of Torino, Regione Gonzole 10, Azienda Ospedaliera S Luigi, 10043 Orbassano, Torino, Italy
    Lung Cancer 34:S91-4. 2001
    ..This 'functional' level would be in keeping with the body's physiological erythropoietin response...
  48. ncbi Chemo-radiotherapy in lung cancer: state of the art with focus on the elderly population
    C Mantovani
    Department of Medical and Surgical Sciences, Radiotherapy Unit, University of Turin, Italy
    Ann Oncol 17:ii61-63. 2006
  49. ncbi Low dose CT in early lung cancer diagnosis: Prevalence data
    Luciano Cardinale
    Istituto di Radiologia, Universita degli Studi di Torino, Polo Ospedale San Luigi Gonzaga, Orbassano, Italy
    Radiol Med 110:532-43. 2005
    ..Lung cancer has a high mortality rate and its prognosis largely depends on early detection. We report the prevalence data of the study on early detection of lung cancer with low-dose spiral CT underway at our hospital...
  50. ncbi The way forward: new drugs and new therapeutic strategies in lung cancer therapy
    Giorgio V Scagliotti
    University of Torino, Department of Clinical and Biological Sciences, Thoracic Oncology Unit, S.Luigi Hospital, Orbassano(Torino, Italy
    Clin Lung Cancer 7:S109-10. 2006
  51. ncbi Fetal adenocarcinoma of the lung in a 25-year-old woman
    Marina Longo
    Thoracic Oncology Unit, Department of Biological and Clinical Sciences, University of Turin, Italy
    J Thorac Oncol 3:441-3. 2008
    ..A pathologic diagnosis of well-differentiated fetal adenocarcinoma of the lung was made and staged as T2N0. Few cases of this type of malignancy have been reported in literature...
  52. ncbi Prospective assessment of XPD Lys751Gln and XRCC1 Arg399Gln single nucleotide polymorphisms in lung cancer
    Daniela F Giachino
    Department of Clinical and Biological Sciences, University of Torino, Turin, Italy
    Clin Cancer Res 13:2876-81. 2007
    ..This study aimed to investigate the relationship between the XPD Lys751Gln and XRCC1 Arg399Gln genotypes and outcome in lung cancer patients...
  53. ncbi The dream is almost over...don't worry, look ahead
    Giorgio V Scagliotti
    Lung Cancer 40:187-90. 2003
  54. ncbi Supportive care in patients with advanced non-small-cell lung cancer
    M Di Maio
    National Cancer Institute Clinical Trials Unit, Naples
    Br J Cancer 89:1013-21. 2003
    ..Chemotherapy does not remarkably affect the pattern of SC, except for some drugs against side effects. Elderly patients assume more drugs for concomitant diseases and receive less antiemetics than adults...
  55. ncbi Informal caregiving burden in advanced non-small cell lung cancer: the HABIT study
    Cesare Gridelli
    Division of Medical Oncology, S G Moscati Hospital, Avellino, Italy
    J Thorac Oncol 2:475-80. 2007
    ..This study's aim was to assess economic data regarding the home assistance burden for advanced non-small cell lung cancer (NSCLC) patients in Italy...
  56. ncbi Consensus report IASLC workshop Bruges, September 2002: pretreatment minimal staging for non-small cell lung cancer
    Pieter E Postmus
    Department of Pulmonary Diseases, Vrije Universiteit Medical Cetner, Amsterdam, Netherlands
    Lung Cancer 42:S3-6. 2003
  57. ncbi Phase II study of pemetrexed-gemcitabine combination in patients with advanced-stage non-small cell lung cancer
    Christian Monnerat
    Institut Gustave Roussy, Villejuif, France
    Clin Cancer Res 10:5439-46. 2004
    ..0%). CONCLUSIONS: This combination had good tolerance and achieved promising overall survival with extended 1- and 2-year survival rates. This cisplatin-free regimen warrants further evaluation in randomized trials...
  58. ncbi Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer
    Mark A Socinski
    Multidisciplinary Thoracic Oncology Program, Lineberger Comprehensive Cancer Center, University of North Carolina, CB 7305, Chapel Hill, NC 27599, USA
    J Clin Oncol 26:650-6. 2008
    ....
  59. ncbi Gemcitabine and cisplatin as induction chemotherapy for patients with unresectable Stage IIIA-bulky N2 and Stage IIIB nonsmall cell lung carcinoma: an Italian Lung Cancer Project Observational Study
    Federico Cappuzzo
    Division of Medical Oncology, Bellaria Hospital, Bologna, Italy
    Cancer 98:128-34. 2003
    ..The objective of this trial was to evaluate the activity and safety of one of the newer platinum-based doublets as a neoadjuvant regimen in patients with unresectable Stage IIIA-bulky N2 and Stage IIIB nonsmall cell lung carcinoma (NSCLC)...
  60. ncbi Gemcitabine and vinorelbine in recurrent head and neck cancer: pharmacokinetic and clinical results
    Mario Airoldi
    Medical Oncology Department, San Giovanni Antica Sede Hospital, Via Cavour 31, 10123 Torino, Italy
    Anticancer Res 23:2845-52. 2003
    ..To evaluate the pharmacokinetic parameters, efficacy and toxicity of a combination of gemcitabine (GEM) and vinorelbine (VNB) in recurrent heavily pre-treated squamous cell head and neck carcinoma...
  61. ncbi Pretreatment quality of life and functional status assessment significantly predict survival of elderly patients with advanced non-small-cell lung cancer receiving chemotherapy: a prognostic analysis of the multicenter Italian lung cancer in the elderly s
    Paolo Maione
    S Giuseppe Moscati Hospital, Avellino, Italy
    J Clin Oncol 23:6865-72. 2005
    ..Using these scores in clinical practice might improve prognostic prediction for treatment planning...
  62. ncbi Transcripts in pretreatment biopsies from a three-arm randomized trial in metastatic non-small-cell lung cancer
    Rafael Rosell
    Department of Oncology, Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain
    Oncogene 22:3548-53. 2003
    ..The predictive value of beta-tubulin III, stathmin and RRM1 should be tested in prospective customized chemotherapy trials, the results of which will help tailor chemotherapy to improve patient survival...
  63. ncbi Lung cancer stage is an independent risk factor for surgical mortality
    Ugo Pastorino
    Istituto Nazionale Tumori, Milan, Italy
    Tumori 94:362-9. 2008
    ..To study surgical mortality and evaluate major risk factors, with specific focus on the role of pathological stage in patients undergoing lung cancer resection...
  64. ncbi Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial
    Cesare Gridelli
    J Natl Cancer Inst 95:362-72. 2003
    ..We compared the effectiveness and toxicity of the combination of vinorelbine plus gemcitabine with those of each drug given alone in an open-label, randomized phase III trial in elderly patients with advanced NSCLC...